VERTEX PHARMACEUTICALS INC / MA Debt Securities, Available-for-sale
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Debt Securities, Available-for-sale of $7.49 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale $7.49B.
- 2025-12-31: Debt Securities, Available-for-sale $7.22B.
- 2023-12-31: Debt Securities, Available-for-sale $8.88B.
- 2023-09-30: Debt Securities, Available-for-sale $6.56B.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2026-06-30 | $7.49B 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $7.22B 10-Q · filed 2026-08-04 | |
| 2023-12-31 | $8.88B 10-K · filed 2024-02-15 | |
| 2023-09-30 | $6.56B 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $6.30B 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $7.64B 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $5.64B 10-K · filed 2024-02-15 | |
| 2022-09-30 | $4.11B 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $5.68B 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $4.88B 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $3.98B 10-K · filed 2023-02-10 | |
| 2021-09-30 | $4.08B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $4.17B 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $4.37B 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $3.62B 10-K · filed 2022-02-09 | $3.62B 10-K · filed 2021-02-11 |
| 2020-09-30 | $3.62B 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $2.97B 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $2.20B 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $1.24B 10-K · filed 2021-02-11 | |
| 2019-09-30 | $1.91B 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $2.00B 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $1.79B 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $1.65B 10-K · filed 2020-02-13 | |
| 2018-09-30 | $1.49B 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $1.38B 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $1.28B 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $1.03B 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |